The global in vivo CRO market size was USD 4.62 billion in 2023, calculated at USD 4.99 billion in 2024 and is expected to be worth around USD 10.89 billion by 2034. The market is slated to expand at 8.11% CAGR from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: In Vivo CRO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. In Vivo CRO Market, by Model Type, 2024-2033
8.1.1. Rodent Based
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Non-Rodent Based
8.1.2.1. Market Revenue and Forecast (2021-2033)
9.1. In Vivo CRO Market, by Modality, 2024-2033
9.1.1. Small Molecules
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Large Molecules
9.1.2.1. Market Revenue and Forecast (2021-2033)
10.1. In Vivo CRO Market, by Indication, 2024-2033
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. CNS Conditions
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Diabetes
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Obesity
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Pain Management
10.1.5.1. Market Revenue and Forecast (2021-2033)
10.1.6. Autoimmune/Inflammation Conditions
10.1.6.1. Market Revenue and Forecast (2021-2033)
10.1.7. Others
10.1.7.1. Market Revenue and Forecast (2021-2033)
11.1. In Vivo CRO Market, by GLP Type, 2024-2033
11.1.1. GLP Toxicology
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Non-GLP
11.1.2.1. Market Revenue and Forecast (2021-2033)
12.1. North America
12.1.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.1.2. Market Revenue and Forecast, by Modality (2021-2033)
12.1.3. Market Revenue and Forecast, by Indication (2021-2033)
12.1.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Modality (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Indication (2021-2033)
12.1.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Modality (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Indication (2021-2033)
12.1.6.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.2.2. Market Revenue and Forecast, by Modality (2021-2033)
12.2.3. Market Revenue and Forecast, by Indication (2021-2033)
12.2.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Modality (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Indication (2021-2033)
12.2.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Modality (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Indication (2021-2033)
12.2.6.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Modality (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Indication (2021-2033)
12.2.7.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Modality (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Indication (2021-2033)
12.2.8.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.3.2. Market Revenue and Forecast, by Modality (2021-2033)
12.3.3. Market Revenue and Forecast, by Indication (2021-2033)
12.3.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Modality (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Indication (2021-2033)
12.3.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Modality (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Indication (2021-2033)
12.3.6.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Modality (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Indication (2021-2033)
12.3.7.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Modality (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Indication (2021-2033)
12.3.8.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.4.2. Market Revenue and Forecast, by Modality (2021-2033)
12.4.3. Market Revenue and Forecast, by Indication (2021-2033)
12.4.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Modality (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Indication (2021-2033)
12.4.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Modality (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Indication (2021-2033)
12.4.6.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Modality (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Indication (2021-2033)
12.4.7.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Modality (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Indication (2021-2033)
12.4.8.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.5.2. Market Revenue and Forecast, by Modality (2021-2033)
12.5.3. Market Revenue and Forecast, by Indication (2021-2033)
12.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Modality (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Indication (2021-2033)
12.5.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Model Type (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Modality (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Indication (2021-2033)
12.5.6.4. Market Revenue and Forecast, by GLP Type (2021-2033)
13.1. IQVIA Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Crown Bioscience
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Taconic Biosciences, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. PsychoGenics Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Evotec
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Janvier Labs
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Biocytogen Boston Corp
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. GemPharmatech
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Charles River Laboratories
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Icon Plc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample